[How should eosinophilic gastroenteropathy be treated?].
Medizinische Klinik C Klinikum der Stadt Ludwighafen, gGmbH, Bremserstrasse, Germany.DMW - Deutsche Medizinische Wochenschrift (Impact Factor: 0.54). 12/2002; 127(46):2464-5. DOI: 10.1055/s-2002-35450
- [Show abstract] [Hide abstract]
ABSTRACT: We report the clinical, laboratory, endoscopic and histopathological findings in a 40-year-old woman with watery diarrhoea and hypoproteinaemia. Elevated alpha(1)-antitrypsin clearance confirmed massive protein-losing enteropathy. Gastroscopic and colonoscopic biopsies showed abundant infiltration of the small bowel wall with eosinophils in proximal duodenum and terminal ileum, respectively. These findings established the diagnosis of eosinophilic gastroenteritis. Both the inflammatory alterations and the severe intestinal protein loss were successfully treated with budesonide, a topically active corticosteroid preparation with controlled small bowel release. The case report illustrates that remission of protein-losing enteropathy secondary to eosinophilic gastroenteritis can be achieved with budesonide, thus supporting its use for this uncommon disease characterised by inflammatory intestinal lesions.Digestive and Liver Disease 02/2006; 38(1):55-9. DOI:10.1016/j.dld.2005.06.013 · 2.96 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.